GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Cambridge University Press (CUP) ; 1982
    In:  Quaternary Research Vol. 18, No. 1 ( 1982-07), p. 91-107
    In: Quaternary Research, Cambridge University Press (CUP), Vol. 18, No. 1 ( 1982-07), p. 91-107
    Abstract: Many cores from the deep basins of the Bering Sea have a thin oxidized zone within otherwise reduced sediment. This oxidized zone began to form about 6000 yr ago and represents an interval of about 3200 yr. Mineralogically, the oxidized and reduced sediments are similar, but chemically they differ. Concentrations of Fe and C are lower, and concentrations of Mn, Ba, Co, Mo, and Ni are higher in the oxidized than in the reduced sediment. Mn is enriched about 10-fold in the oxidized zone relative to its concentration in the reduced sediment, Mo about threefold, and Ba, Co, and Ni about twofold. These data suggest that the oxidized zone developed diagenetically as the result of the balance between the flux of organic matter and the available dissolved oxygen in bottom and interstitial waters. We propose that the Bering Sea was substantially ice covered when global glacial conditions prevailed. during the transition to global interglacial conditions, seasonal meltwater from thawing sea ice formed a lens of fresh water that decreased organic productivity. During the winter seasons, however, sea ice reformed and caused downwelling of dense, oxygen-rich waters to recharge bottom waters. The combination of lower organic productivity and more oxygen-rich bottom water allowed oxidized sediment to accumulate. Once full interglacial conditions were established, the volume of sea ice produced was insufficient to affect either productivity or the supply of dissolved oxygen and so bottom conditions again became reducing. Similar events probably occurred during the onset of global glacial conditions, and similar oxidized layers probably formed at these times. Such oxidized zones are highly unstable, however, in a reducing environment and, once buried beyond the influence of bacterial and infaunal activities, are depleted of their available oxygen and converted to reduced sediment.
    Type of Medium: Online Resource
    ISSN: 0033-5894 , 1096-0287
    RVK:
    Language: English
    Publisher: Cambridge University Press (CUP)
    Publication Date: 1982
    detail.hit.zdb_id: 1471589-2
    detail.hit.zdb_id: 205711-6
    SSG: 13
    SSG: 14
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cephalalgia, SAGE Publications, Vol. 39, No. 11 ( 2019-10), p. 1343-1357
    Abstract: To address the need for long-term lasmiditan data, the GLADIATOR study evaluated the safety (primary) and efficacy (secondary) of lasmiditan for the intermittent, acute treatment of migraine attacks for up to 1 year. Methods In this prospective, randomized, open-label, Phase 3 study, patients who had completed either of two single-attack studies were offered the opportunity to be randomized 1:1 to lasmiditan 100 mg or 200 mg. Patients were asked to use lasmiditan as the first treatment for each new migraine attack of at least moderate severity. Assessments occurred at baseline and at prespecified time increments up to 48 hours after each dose of study drug using an electronic diary, and safety was assessed throughout the study. Migraine Disability Assessment (MIDAS) was assessed at each visit. Results As of the cut-off date for this interim analysis (6 March 2018), 1978 patients had received ≥ 1 lasmiditan dose and treated 19,058 migraine attacks. Overall, treatment-emergent adverse events (TEAEs) were similar to those in the single-attack studies and included dizziness (18.6%), somnolence (8.5%), and paresthesia (6.8%). The frequency of TEAEs generally decreased with subsequent attacks. No treatment-related serious adverse events and no cardiovascular TEAEs potentially due to vasoconstriction were observed. For both lasmiditan doses, efficacy measures were generally consistent over study quarters and treated attacks. Overall, across all treated attacks at 2 hours post-dose, pain freedom was observed in 26.9% of the attacks treated with lasmiditan 100 mg and 32.4% of the attacks treated with lasmiditan 200 mg. MIDAS total scores decreased over time. Conclusions The interim results of this long-term study showed intermittent lasmiditan (100 mg and 200 mg) to be generally well tolerated and efficacious for the acute treatment of migraine over a 1-year period. Trial registration number: NCT02565186; https://clinicaltrials.gov/ct2/show/NCT02565186
    Type of Medium: Online Resource
    ISSN: 0333-1024 , 1468-2982
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2019
    detail.hit.zdb_id: 2019999-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Elsevier BV ; 2018
    In:  Technological Forecasting and Social Change Vol. 137 ( 2018-12), p. 211-225
    In: Technological Forecasting and Social Change, Elsevier BV, Vol. 137 ( 2018-12), p. 211-225
    Type of Medium: Online Resource
    ISSN: 0040-1625
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 2015184-6
    detail.hit.zdb_id: 280700-2
    SSG: 19,2
    SSG: 3,4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cephalalgia Reports, SAGE Publications, Vol. 3 ( 2020-01-01), p. 251581632095817-
    Abstract: GLADIATOR was a prospective, randomized, open-label, phase 3 study of lasmiditan 100 mg or 200 mg dosed intermittently for up to 1 year in patients with episodic migraine. Most patients had completed one of two single-attack studies before participation. A total of 2030 patients received ≥1 lasmiditan dose and 19,879 migraine attacks were treated. Safety results were similar to the previously reported interim analysis. The most frequently reported treatment-emergent adverse events (TEAEs) included dizziness (18.5%), somnolence (8.5%), and paresthesia (6.8%), with frequency of adverse events appearing to decrease with subsequently treated attacks. At 2 h post-dose, 26.7% and 32.2% of all attacks treated with lasmiditan 100 mg and 200 mg, respectively, were pain free. This pattern was generally consistent across study quarters and treated attacks. In conclusion, during a 1-year treatment period, intermittent lasmiditan for episodic migraine treatment was associated with generally decreasing TEAEs and consistent efficacy.
    Type of Medium: Online Resource
    ISSN: 2515-8163 , 2515-8163
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2020
    detail.hit.zdb_id: 2964311-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...